Live Enforcement Tracker

Regulatory Signals & Claim Pattern Intelligence

Live Telemetry Active·Last reviewed: 2026-07-02

Agency	Market	Claim Pattern	Severity	Source	Action
FDA	Compounded GLP-1 / Telehealth	FDA-approved implication; brand-equivalence phrasing	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Med Spa & Wellness	False/misleading compounded GLP-1 claims; implied equivalence to FDA-approved drugs (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	FDA-approved implication; clinically-proven phrasing	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Weight Loss Clinic	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / IV & Wellness	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page
FDA	Compounded GLP-1 / Telehealth	False/misleading claims for compounded semaglutide/tirzepatide (FD&C Act §502(a), §502(bb))	High	Source	Check My Page

20 active signals tracked·20 high severity·1 agencies

Is your page language close to one of these patterns?

AuditGPT reviews your GLP-1 or med-spa page against the patterns regulators have already cited. Returns safer rewrites with a dated review record. Not legal, clinical, or regulatory advice.

Request a Claim Exposure Audit

Enforcement Data Feed

Weekly claim-pattern brief and structured data feed for compliance teams, agencies, and health-market operators. Spreadsheet access available for early partners.

Ask about feed access